Lenvima 10mg Capsule

About

Lenvima 10mg Capsule contains lenvatinib, a potent multi-kinase inhibitor designed to target key receptors involved in tumor growth and angiogenesis. It specifically inhibits the kinase activities of VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR2, FGFR3, FGFR4, PDGFRα, KIT, and RET. This broad spectrum of inhibition effectively disrupts the signaling pathways that drive cancer cell proliferation, survival, and the formation of new blood vessels essential for tumor sustenance. The 10mg strength is often used in specific dosing regimens or for patients requiring higher therapeutic concentrations, playing a critical role in the management of advanced malignancies where these pathways are overactive.

Uses

• Treatment of differentiated thyroid cancer (DTC) refractory to radioactive iodine.
• Management of advanced renal cell carcinoma (RCC) in combination with everolimus.
• First-line treatment for unresectable hepatocellular carcinoma (HCC).
• Treatment of advanced endometrial carcinoma in combination with pembrolizumab.

Directions For Use

Take orally once daily with or without food, at approximately the same time each day. Swallow the capsule whole.

Benefits

• Comprehensive inhibition of multiple oncogenic kinases.
• Demonstrated efficacy in various advanced cancers.
• Helps to control tumor progression and growth.
• Offers a valuable option for difficult-to-treat cancers.
• Convenient oral administration.
• Improves progression-free survival in specific patient populations.

Side Effects

• Hypertension (high blood pressure)
• Fatigue and asthenia
• Diarrhea
• Decreased appetite
• Weight loss
• Nausea and vomiting
• Proteinuria (protein in urine)
• Hand-foot syndrome (palmar-plantar erythrodysesthesia)
• Hypothyroidism
• Headache
• Dysphonia (hoarseness)
• Abdominal pain

Safety Measures

• Alcohol - Avoid excessive alcohol consumption as it may exacerbate liver-related side effects or interact with the medication.
• Pregnancy - Contraindicated during pregnancy due to potential fetal harm. Women of childbearing potential must use effective contraception.
• Breastfeeding - Breastfeeding is not recommended during treatment and for at least one week after the last dose due to potential harm to the infant.
• Liver - Use with caution and dose adjustment may be required in patients with moderate to severe hepatic impairment.
• Kidney - Dose adjustment may be necessary for patients with severe renal impairment. Monitor renal function regularly.
• Lung - Monitor for signs of pulmonary embolism or interstitial lung disease, though these are rare.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.